Literature DB >> 2529291

Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients.

M Maj1, R Pirozzi, F Starace.   

Abstract

The response to lithium prophylaxis was assessed in a sample of bipolar patients subdivided into the following groups on the basis of the previous pattern of course of their illness: MDI (sequence mania-depression-free interval), DMI (sequence depression-mania-free interval), CC-LC (continuous circular course with long cycles), CC-RC (continuous circular course with rapid cycles), IRR (irregular course). A significant reduction of the mean number of morbid episodes and of the mean total morbidity during lithium treatment was observed only in patients with a previous MDI or IRR course. The percentage of responders to prophylaxis was significantly different among the five groups, and the difference could be mainly ascribed to the high response rate in the MDI group and the low response rate in the DMI and CC-RC groups. These results suggest that the classification of bipolar patients according to the previous pattern of course of their illness may be useful for the prediction of lithium response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2529291     DOI: 10.1016/0165-0327(89)90005-0

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  13 in total

1.  Depression following mania.

Authors:  L Tondo; R J Baldessarini
Journal:  Mol Psychiatry       Date:  2016-04-26       Impact factor: 15.992

Review 2.  A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.

Authors:  R M Post; S R Weiss
Journal:  Mol Neurobiol       Date:  1996-08       Impact factor: 5.590

Review 3.  Rapid cycling bipolar disorder: clinical characteristics and treatment options.

Authors:  William Coryell
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management.

Authors:  Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

5.  Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder.

Authors:  S L Dubovsky; M Thomas; A Hijazi; J Murphy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

6.  Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians.

Authors:  Raphael J. Leo; Rajesh Narendran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

Review 7.  Pharmacological treatment of adult bipolar disorder.

Authors:  Ross J Baldessarini; Leonardo Tondo; Gustavo H Vázquez
Journal:  Mol Psychiatry       Date:  2018-04-20       Impact factor: 15.992

8.  Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients.

Authors:  Anne Berghöfer; Martin Alda; Mazda Adli; Christopher Baethge; Michael Bauer; Tom Bschor; Paul Grof; Bruno Müller-Oerlinghausen; Janusz K Rybakowski; Alexandra Suwalska; Andrea Pfennig
Journal:  Int J Bipolar Disord       Date:  2013-07-31

9.  Free Interval Duration: Clinical Evidence of the Primary Role of Excitement in Bipolar Disorder.

Authors:  Gabriele Sani; Alessio Simonetti; Daniela Reginaldi; Alexia E Koukopoulos; Antonio Del Casale; Giovanni Manfredi; Georgios D Kotzalidis; Paolo Girardi
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

10.  A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder.

Authors:  R O Brady; A Cooper; J E Jensen; N Tandon; B Cohen; P Renshaw; M Keshavan; D Öngür
Journal:  Transl Psychiatry       Date:  2012-09-11       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.